Intelligence · Drug directory
Obesity & Metabolic Drugs
GLP-1, GIP/GLP-1 dual agonists, and metabolic disease therapies including obesity and type 2 diabetes treatments.
Quick answer
Obesity & metabolic drugs: NovaPharmaNews indexes 4 pharmaceutical drugs in this therapeutic segment with regulatory status, pipeline programs, patents, and congress coverage cross-links. GLP-1, GIP/GLP-1 dual agonists, and metabolic disease therapies including obesity and type 2 diabetes treatments.
-
liraglutide
SAXENDA Teva Pharma GmbH
A10BJ02 -
semaglutide
OZEMPIC NovoThirteen
A10BJ06 -
tirzepatide
MOUNJARO
A10BX16 -
metabolically
Frequently asked questions
How many obesity & metabolic drugs are in the directory?
4 drug profiles match this therapeutic area filter based on class, mechanism, target, and INN metadata.
How are drugs assigned to a therapeutic area?
Classification uses WHO therapeutic class, mechanism of action, molecular target, and INN pattern matching against curated oncology, metabolic, CNS, rare disease, and immunology taxonomies.